Sun Pharmaceutical receives warning letter from USFDA for Halol facility

The Halol facility was placed under Import Alert by USFDA.

Sun Pharmaceutical gets OAI from USFDA for Mohali facility

Sun Pharma gets OAI from USFDA for Halol facility

The OAI classification implies that the US FDA may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved

Sun Pharma Chairman Israel Makov to retire on completion of term

He was appointed a Board member and the Chairman in 2012.

Sun Pharma and Cosmo announce territory expansion of license and supply agreements for WINLEVI

Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.

Sun Pharma acquires Uractiv portfolio from Fiterman Pharma in Romania

The acquisition is subject to customary closing conditions and necessary regulatory approvals. The financial terms of the transaction are confidential

Sun Pharma to launch Brillo, a first-in-class oral lipid-lowering drug in India

Bempedoic Acid administered as a 180-mg dose, is approved by the USFDA and European Union for the treatment of hypercholesterolemia

Sun Pharma gets exclusive patent licence for Vortioxetine

Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults

Sun Pharma Advanced Research Company Q3FY22 loss at Rs. 15.84 crore

Sun Pharma Advanced Research Company has reported standalone financial results for the period ended December 31, 2021

Sun Pharma demonstrates strong performance on all fronts: ICICI Direct

Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses